2025-04-11 - Analysis Report
## Teladoc Health Inc (TDOC) Stock Report

**0. Key Figures:**

* **Cumulative Return (TDOC):** -69.38%
* **Cumulative Return (VOO):** 62.24%
* **Return Difference (TDOC vs VOO):** -131.6%
* **Relative Divergence:** 4.5% (indicates TDOC's performance is significantly below VOO, but within the lower range of historical divergence)
* **Current Price:** $7.24


**1. Company Overview and Performance Comparison:**

Teladoc Health Inc. is a telehealth company providing virtual healthcare services.  The company's cumulative return significantly underperforms the S&P 500 (VOO) by 131.6 percentage points, indicating substantial underperformance.  The provided Alpha and Beta analysis shows high volatility and negative alpha in recent years, suggesting poor risk-adjusted returns relative to the market.


**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 76.0% | 60.6% | 52.0% | -0.0 | 6.7 |
| 2016-2018  | 128.0% | 59.3% | 112.0% | -0.0 | 9.5 |
| 2017-2019  | 176.0% | 59.3% | 149.0% | 0.3 | 16.0 |
| 2018-2020  | 237.0% | 64.0% | 212.0% | 0.1 | 38.1 |
| 2019-2021  | -83.0% | 64.0% | -136.0% | 0.1 | 17.5 |
| 2020-2022  | -295.0% | 81.3% | -300.0% | 0.0 | 4.5 |
| 2021-2023  | -488.0% | 81.3% | -504.0% | -0.6 | 4.1 |
| 2022-2024  | -111.0% | 81.3% | -127.0% | -0.8 | 1.7 |
| 2023-2025  | -40.0% | 72.9% | -53.0% | -0.8 | 1.4 |


The table shows periods of extremely high growth followed by substantial declines, culminating in significant negative CAGR in recent years.  High Beta values indicate sensitivity to market movements, and the negative Alpha in recent periods points to consistent underperformance against the market benchmark.


**2. Recent Price Movement:**

* **Closing Price:** $7.24
* **5-Day Moving Average:** $7.36
* **20-Day Moving Average:** $8.077
* **60-Day Moving Average:** $9.8198

The stock price is currently below all three moving averages, suggesting a downtrend.  The recent price change of -8.12% indicates a significant one-day drop.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4292 (Medium Risk)
* **RSI:** 33.24 (suggests the stock is in oversold territory)
* **PPO:** -0.1886 (negative value indicates bearish momentum)
* **Recent Relative Divergence Change:** -0.2 (short-term downtrend)
* **Expected Return:** -1720.7% (This extremely negative expected return needs further clarification and likely reflects the current market sentiment and historical performance).


The technical indicators suggest bearish sentiment. The extremely negative expected return warrants further investigation and context.  The large negative price change (-8.12%) highlights a significant recent downward movement.


**4. Recent Earnings Analysis:**

| Date       | EPS      | Revenue     |
|------------|----------|-------------|
| 2024-10-31 | -$0.19   | $0.64 B     |
| 2024-08-01 | -$4.92   | $0.64 B     |
| 2024-04-26 | -$0.49   | $0.65 B     |
| 2023-10-27 | -$0.35   | $0.66 B     |
| 2024-10-31 | -$0.35   | $0.66 B     |

The company has consistently reported negative EPS in recent quarters, indicating ongoing losses.  Revenue remains relatively stable, but the lack of profitability is a major concern.  The significant negative EPS in August 2024 is particularly noteworthy and requires further investigation.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.64B | 70.50% |
| 2024-09-30 | $0.64B | 71.94% |
| 2024-06-30 | $0.64B | 70.73% |
| 2024-03-31 | $0.65B | 69.89% |
| 2023-12-31 | $0.66B | 70.72% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $1.49B | -3.25% |
| 2024-09-30 | $1.51B | -2.21% |
| 2024-06-30 | $1.50B | -55.77% |
| 2024-03-31 | $2.29B | -3.58% |
| 2023-12-31 | $2.33B | -1.24% |

Despite relatively stable revenue and high profit margins, the negative ROE across all recent quarters indicates a significant problem with the company's profitability relative to its equity. The extremely low ROE in Q2 2024 requires further explanation.


**6. Overall Analysis:**

Teladoc Health (TDOC) is currently experiencing a significant downturn, significantly underperforming the S&P 500. Negative EPS, consistently negative ROE, and bearish technical indicators paint a concerning picture. While the high profit margin might seem positive, it's overshadowed by the substantial losses.  The extremely negative expected return highlights the high risk associated with the investment.  Further investigation into the causes of the August 2024 EPS drop and the Q2 2024 ROE is crucial before making any investment decisions. A long-term investment strategy should carefully consider the inherent volatility and the company's ability to turn its financial performance around.  The -1720.7% expected return is likely highly influenced by the recent severe decline and should be treated with extreme caution.  More detailed fundamental analysis and industry comparison are needed for a more complete assessment.
